Design Therapeutics (DSGN) Income from Continuing Operations (2020 - 2026)
Design Therapeutics recorded quarterly Income from Continuing Operations of 17636000.0 in Q1 2026, down 10.25% quarter-over-quarter from 15997000.0 in Q4 2025, and little changed year-over-year from 17557701.47 in Q1 2025.
Design Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 17636000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations changed 0.45% year-over-year to 17636000.0; the TTM figure through Mar 2026 stood at 69713000.0 (down 24.05% YoY), while the FY2025 annual figure was 69792000.0, down 40.74% from the prior year.
- Income from Continuing Operations came in at 17636000.0 for Q1 2026 at Design Therapeutics, down from 15997000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11105000.0 in Q1 2024 to a low of 22596000.0 in Q2 2023.
- A 5-year average of 16635235.29 and a median of 16997000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 135.39% in 2022 and surged 48.71% in 2024, its largest moves.
- Design Therapeutics' Income from Continuing Operations stood at 19392000.0 in 2022, then grew by 22.02% to 15121000.0 in 2023, then increased by 9.72% to 13651000.0 in 2024, then fell by 17.19% to 15997000.0 in 2025, then fell by 10.25% to 17636000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 17636000.0, 15997000.0, and 16997000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | -17.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.64 Mn |
| Dec 31, 2025 | -16.00 Mn |
| Sep 30, 2025 | -17.00 Mn |
| Jun 30, 2025 | -19.08 Mn |
| Mar 31, 2025 | -17.72 Mn |
| Dec 31, 2024 | -13.65 Mn |
| Sep 30, 2024 | -13.04 Mn |
| Jun 30, 2024 | -11.79 Mn |
| Mar 31, 2024 | -11.11 Mn |
| Dec 31, 2023 | -15.12 Mn |
| Sep 30, 2023 | -18.82 Mn |
| Jun 30, 2023 | -22.60 Mn |
| Mar 31, 2023 | -21.65 Mn |
| Dec 31, 2022 | -19.39 Mn |
| Sep 30, 2022 | -19.19 Mn |
| Jun 30, 2022 | -15.64 Mn |
| Mar 31, 2022 | -13.37 Mn |
| Dec 31, 2021 | -11.13 Mn |
| Sep 30, 2021 | -11.34 Mn |
| Jun 30, 2021 | -7.69 Mn |
| Mar 31, 2021 | -5.68 Mn |
| Dec 31, 2020 | -3.86 Mn |
| Sep 30, 2020 | -2.38 Mn |
| Jun 30, 2020 | -1.46 Mn |
| Mar 31, 2020 | -623,000.00 |